Navigation Links
Does apolipoprotein E mimetic peptide reduce neuronal apoptosis induced by DBI?
Date:5/27/2014

Because the majority of patients with diffuse brain injury are not suitable candidates for surgery, neuroprotective agents are of great importance. Apolipoprotein E exerts a neuroprotective effect against brain injury, but synthetic apolipoprotein E cannot cross the blood-brain barrier, thus limiting its application.It has been reported that apolipoprotein E (138) mimetic peptide can cross the blood-brain barrier in both normal and injured brain. However, its impact on neurological function following diffuse brain injury is still unclear. Prof. Jianmin Li and team from the Affiliated Hospital of Hebei United University in China conducted a relevant study. These researchers found that apolipoprotein E-derived therapeutic peptide (0.6mg/kg and 1.2mg/kg) improved synaptic stability and improved learning and memory performance after diffuse brain injury. Furthermore, apolipoprotein E mimetic peptide protected against brain injury by reducing oxidative stress, thereby suppressing the ERK1/2-Bax mitochondrial apoptotic pathway and decreasing neuronal death. These results have been published in the Neural Regeneration Research (Vol. 9, No. 5, 2014).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert

Page: 1

Related biology news :

1. 3-D biomimetic scaffolds support regeneration of complex tissues from stem cells
2. Chemists work with small peptide chains may revolutionize study of enzymes and diseases
3. Small peptides as potential antibiotics
4. Newly discovered human peptide may become a new treatment for diabetes
5. US Peptides Updates Website with New Information
6. Extreme Peptide Announces that its EP Reward Points Program is Now Easier than Ever to Use
7. Arg-Phe-amide-related peptides influence gonadotropin-releasing hormone neurons
8. A peptide to protect brain function
9. US Peptides Discusses HGH and Growth Hormone Releasing Peptides and How They Affect Performance
10. Intranasal neuropeptide Y may offer therapeutic potential for post-traumatic stress disorder
11. Cell-permeable peptide shows promise for controlling cardiovascular disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... JOSE, Calif. , Jan. 20, 2016 /PRNewswire/ ... developer of human interface solutions, today announced sampling ... controller solution for wearables and small screen applications ... such as printers. Supporting round and rectangular shapes, ... S1423 offers excellent performance with moisture on screen, ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
(Date:2/4/2016)... , February 4, 2016 Strasbourg, ... (ABL), Inc. --> Strasbourg, France , ... --> PharmaVentures is pleased to announce that it acted ... biopharmaceutical manufacturing unit in Strasbourg, France , ... --> --> Transgene (Euronext: TNG), ...
(Date:2/3/2016)... Feb. 3, 2016  Discovery Laboratories, Inc. (NASDAQ: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, ... approved an inducement award as a component of ... newly appointed President and Chief Executive Officer.  The ... on February 1, 2016 and granted as an ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered organ ... and bronchus, today announced that CEO Jim ... CEO & Investor Conference on Tuesday, February ... New York City . HART,s presentation ...
Breaking Biology Technology: